Anti-PD-1 immune checkpoint blockade-based therapy using pembrolizumab in a patient with high-grade glioblastoma. (2023). Biomedical Research and Therapy, 10(5), 5680-5685. https://doi.org/10.15419/bmrat.v10i5.809